DOES A MANDATORY SWITCH FROM ORIGINATOR ADALIMUMAB TO BIOSIMILAR GP2017 OR SB5 LEAD TO INCREASED HOSPITAL COSTS? A DANBIO STUDY OF >1,300 PATIENTS WITH INFLAMMATORY ARTHRITIS

被引：1
|
作者：
Nabi, H. [1 ,2 ]
Ibsen, R. [3 ]
Ibsen, M. [3 ]
Kjellberg, J. [4 ]
Hetland, M. L. [1 ,2 ]
Glintborg, B. [1 ,2 ]
机构：
[1] Copenhagen Univ Hosp, Rigshosp, DANBIO & Copenhagen Ctr Arthrit Res COPECARE, Ctr Rheumatol & Spine Dis,Ctr Head & Orthoped, Glostrup, Denmark
[2] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark
[3] i2minds, Aarhus, Denmark
[4] Danish Ctr Social Sci Res, VIVE, Copenhagen, Denmark
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
D O I：
10.1136/annrheumdis-2023-eular.812
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0376
引用
收藏
页码：441 / 442
页数：2
相关论文
共 15 条
  • [1] Does a mandatory switch from originator adalimumab to biosimilar GP2017 or SB5 lead to increased hospital costs? A DANBIO study of >1,300 patients with inflammatory arthritis
    Nabi, H.
    Ibsen, R.
    Ibsen, M.
    Kjellberg, J.
    Hetland, M.
    Glintborg, B.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023, 52 : 107 - 108
  • [2] NON MEDICAL SWITCH FROM ADALIMUMAB ORIGINATOR TO THE BIOSIMILAR GP2017 IN PATIENTS AFFECTED BY CHRONIC ARTHRITIS
    Colaci, M.
    Aprile, M. L.
    La Rosa, A.
    Di Maggio, A.
    Malatino, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1135 - 1135
  • [3] Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study
    Sieborg, Johan
    Maul, Julia-Tatjana
    Wu, Jashin J.
    Loft, Nikolai Nguyen
    Skov, Lone
    Bryld, Lars Erik
    Rasmussen, Mads Kirchheine
    Dam, Tomas Norman
    Bertelsen, Trine
    Ajgeiy, Kawa Khaled
    Thomsen, Simon Francis
    Thyssen, Jacob P.
    Egeberg, Alexander
    Thein, David
    ACTA DERMATO-VENEREOLOGICA, 2025, 105
  • [4] Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study
    Scrivo, R.
    Castellani, C.
    Mancuso, S.
    Sciarra, G.
    Giardina, F.
    Bevignani, G.
    Ceccarelli, F.
    Spinelli, F. R.
    Alessandri, C.
    Di Franco, M.
    Riccieri, V.
    Priori, R.
    Conti, F.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (03) : 613 - 619
  • [5] Evaluation of the safety and effectiveness after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting
    Deprez, N.
    De Somer, T.
    Baert, D.
    Deceuninck, M.
    Huys, I.
    Mattens, V.
    Sterckx, A.
    Vanderstraeten, E.
    Vandervoort, J.
    Van Heddegem, N.
    Dewint, P.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2022, 85 (04) : 557 - 564
  • [6] Acceptance of switch, patient satisfaction and adverse events after switch from adalimumab originator to biosimilar SB5 in patients with Inflammatory Bowel Disease in a real-life setting
    De Somer, T.
    Deprez, N.
    Baert, D.
    Deceuninck, M.
    Huys, I.
    Mattens, V.
    Sterckx, A.
    Vanden Branden, S.
    Vanderstraeten, E.
    Vandervoort, J.
    Van Heddegem, N.
    Dewint, P.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S406 - S406
  • [7] Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis
    Glintborg, Bente
    Ibsen, Rikke
    Bilbo, Rebecca Elisabeth Qwist
    Hetland, Merete Lund
    Kjellberg, Jakob
    RMD OPEN, 2019, 5 (02):
  • [8] Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis
    Glintborg, B.
    Sorensen, J.
    Hetland, M. L.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 : 58 - 59
  • [9] Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis
    Glintborg, Bente
    Sorensen, Jan
    Hetland, Merete Lund
    RMD OPEN, 2018, 4 (02):
  • [10] Does a Mandatory Non-medical Switch from Originator to Biosimilar Etanercept Lead to Increase in Healthcare Use and Costs? A Danish Register-based Study of 1620 Patients with Inflammatory Arthritis
    Glintborg, Bente
    Ibsen, Rikke
    Bilbo, Rebekka Elisabeth Qwist
    Hetland, Merete Lund
    Kjellberg, Jakob
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
12